Impact of a Pilot Outreach Program upon Provider Awareness and Prescribing of a Concerning Opioid Combination Regimen by Santaniello, Briana et al.
University of Massachusetts Medical School 
eScholarship@UMMS 
Commonwealth Medicine Publications Commonwealth Medicine 
2018-02-22 
Impact of a Pilot Outreach Program upon Provider Awareness and 
Prescribing of a Concerning Opioid Combination Regimen 
Briana Santaniello 
Magellan Rx Management 
Et al. 
Let us know how access to this document benefits you. 
Follow this and additional works at: https://escholarship.umassmed.edu/commed_pubs 
 Part of the Health Economics Commons, Health Law and Policy Commons, Health Policy Commons, 
Health Services Administration Commons, Health Services Research Commons, Pharmaceutical 
Preparations Commons, Pharmacy Administration, Policy and Regulation Commons, Substance Abuse 
and Addiction Commons, and the Therapeutics Commons 
Repository Citation 
Santaniello B, Pomfret TC, Tesell MA, Trask NM, Alper CJ, Clements KM, Palumbo V, Lenz K, Jeffrey PL. 
(2018). Impact of a Pilot Outreach Program upon Provider Awareness and Prescribing of a Concerning 
Opioid Combination Regimen. Commonwealth Medicine Publications. https://doi.org/10.13028/aafy-
q316. Retrieved from https://escholarship.umassmed.edu/commed_pubs/184 
This material is brought to you by eScholarship@UMMS. It has been accepted for inclusion in Commonwealth 
Medicine Publications by an authorized administrator of eScholarship@UMMS. For more information, please contact 
Lisa.Palmer@umassmed.edu. 
DISCUSSION
• A total of 44% of members had “positive 
changes” to their regimen 180 days post-
intervention. There were 51% of members  
with no change or an increase in regimen 
complexity (i.e., dose increases or addition  
of another medication of concern), which  
included 33% of members overall with no 
changes 180 days post-intervention.
• Upon outreach, the most common reasons prescribers indicated they would not make 
changes to the combination regimen were stability on the regimen (38%) and lack of 
control over the prescribing abilities of other providers (24%).
• Sole prescribers were generally receptive to considering changes to the regimen after 
TPO, as 67% of these prescribers made “positive changes” to regimens 180 days post-
intervention. 
• While OD/DRH outcomes were not significantly reduced in the post-intervention period 
compared to the pre-intervention period, a TPO program may represent a value for 
managed care organizations by increasing prescriber awareness of medication regimens, 
which may represent a health risk for members. Outreach programs may also benefit from 
TPO occurring earlier in the course of a member receiving a concerning combination of 
medications to limit the amount of members that are “stabilized” on such a regimen.
LIMITATIONS
• The sample size was relatively small which may limit the generalizability of the results.
• Pharmacy claims are not necessarily indicative of the way medications are utilized.
• Members may have been excluded from the study if out-of-pocket payments were made 
as investigators did not have access to the prescription monitoring program; therefore,  
the true sample size for this Medicaid population may be underestimated.
• Not all prescribers were successfully contacted, often due to inaccurate workplace listings 
or contact numbers.
• SUD diagnoses were derived from billed medical claims which are occasionally prone 
to coding errors. This could have resulted in overestimation of SUD diagnoses in this 
population.
OBJECTIVES
• To evaluate prescriber awareness of the presence and risks of this medication combination 
among members under their care.
• To evaluate changes to members’ regimens 180 days post-intervention and compare drug 
overdose/drug-related hospitalizations (OD/DRH) 180 days pre- and post-intervention.
METHODS
Pharmacy and medical claims histories for each Medicaid fee-for-service member that had 
paid claims for a combination of opioids, BZDs, gabapentin, and stimulants for ≥120 days 
during a 180-day period between March 1, 2015 and August 31, 2015 were included. 
• Pharmacy claims data evaluated included:
 – Medication name, strength and days’ supply
 – Calculated morphine equivalent dose per day (MED) of the opioid
• Medical claims data evaluated included:
 – Behavioral health, pain and substance use diagnoses, including substance use disorder 
(SUD)-related diagnoses
 – Medical services rendered for these diagnoses, including hospitalizations, emergency room 
visits, and office visits
• Inclusion criteria:
 – Age ≥18 years
 – Active coverage during study period
 – Continued combination treatment at the time of outreach
• Exclusion criteria:
 – Disruptions in Medicaid coverage, including the presence of third party insurance coverage 
during the study period
 – Pregnancy
 – Prescription filled for buprenorphine or buprenorphine/naloxone from the beginning of the 
study period to the time of TPO
•  TPO was conducted with each prescriber who prescribed any component of 
the regimen. Discussion focused upon:
 – Prescriber awareness of the combination regimen (if not sole prescriber)
 – Safety concerns with the use of this combination of medications
 – Indications for use of  each medication in the regimen
 – Potential for changing the regimen and alternative medications considered and/or prescribed
 – Rationale for chronic benzodiazepine use in the absence of an antidepressant for the 
management of anxiety
 – Pain Medicine or other specialist involvement
 – Future treatment plans
RESULTS
CONCLUSIONS
• The TPO program alerted 26% of prescribers contacted that the member was on the 
targeted medication combination. 
• Although over 40% of members who had at least one prescriber contacted had a 
“positive change” in their regimen, there was no change in OD/DRH outcomes. 
• Further study in a larger sample size is warranted to assess the impact of improving 
awareness of the concerning combination of opioids, BZDs, gabapentin, and stimulants 
upon OD/DRH outcomes, including the use of additional interventions.
BACKGROUND
• From 2000 to 2014, the rate of overdose deaths involving opioids in the United States 
increased by 200%.1 Between 1996 and 2013, the number of overdoses involving anxiety 
medications increased by 300%.2
• Drug utilization review within a large Medicaid population revealed the co-prescribing of 
opioids with benzodiazepines (BZDs), gabapentin, and stimulants was seen in over 500 
members. The concomitant use of these agents is associated with numerous health risks, 
including additive central nervous system depression, potential for misuse and abuse,  
and overdose.3
• Given the safety concerns regarding the concomitant use of these medications, a telephonic 
prescriber outreach (TPO) program was developed to assess prescriber awareness about 
the concomitant use of these medications.
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A total of 521 unique members had continuous pharmacy claims for ≥120 days of 
therapy with opioids, BZDs, gabapentin, and stimulants. Interruptions in Medicaid 
coverage and regimen changes were the most common reasons for exclusion. (Figure 1)
There were 64 unique prescribers (Figure 2) for the 39 unique members included in  
the study, resulting in contact with at least one prescriber for 32 of 39 members (82%).
Contact was achieved with 47 of 64 prescribers (73%).
Upon TPO, 36 of 47 prescribers contacted were aware of the member’s entire  
regimen or were the sole prescriber (77%) and 12 prescribers were unaware of  
the member’s entire regimen (26%). One prescriber was counted twice, as they  
were not aware of the combination regimen in all members under their care. (Figure 3)
Pharmacy claims analysis 180 days post-intervention revealed 14 of 32 (44%)  
members who had at least one prescriber contacted had a dose reduction or 
discontinuation of at least one targeted medication (“positive change”). (Figure 4)
There was a reduction in OD/DRH by one event from the pre-intervention to  
post-intervention period.
SUD diagnoses were relatively common, as 38% of members had a SUD diagnosis 
in their medical claims history.
The majority of members were on opioids at MED <100 mg (56%), 8% of members  
were on MED 100 to 200 mg, and 13% of members were on MED >200 mg.  
The remaining 23% were taking tramadol, which was not converted to MED. 
